1-1 of 1
Bao Lam
Close
Sort by
Journal Articles

A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD–mutant acute myeloid leukemia

Clinical Trials & Observations
Catherine C. Smith, Mark J. Levis, Olga Frankfurt, John M. Pagel, Gail J. Roboz, Richard M. Stone, Eunice S. Wang, Paul L. Severson, Brian L. West, Mai H. Le, Sabine Kayser, Bao Lam, Henry H. Hsu, Chao Zhang, Gideon Bollag, Alexander E. Perl
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1711–1721.
https://doi.org/10.1182/bloodadvances.2020001449
Published: 2020
Includes: Supplemental data